Clinical trial
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic…
NCT00052845 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00052845 |
|---|---|
| Title | Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, estramustine phosphate sodium, exisulind |
| Enrollment | 80 |
| Start date | Nov 1, 2002 |
| Primary completion | Jan 1, 2006 |
| Completion | Apr 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 1, 2016 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: